(Q34990771)

5 August 2017

1 reference

title

The psychiatric side-effects of rimonabant (English)

1 reference

José Alexandre de Souza Crippa

5 August 2017

series ordinal

2

object named as

José Alexandre S Crippa

1 reference

5 August 2017

Fabrício A Moreira

1

1 reference

5 August 2017

1 June 2009

1 reference

Brazilian Journal of Psychiatry

5 August 2017

1 reference

5 August 2017

31

1 reference

5 August 2017

2

1 reference

5 August 2017

145-153

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

5 August 2017

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

A random walk through a cannabis field

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Cannabis, the mind and society: the hash realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

History of cannabis as a medicine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

The molecular logic of endocannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Cannabinoid receptor localization in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Adverse effects of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Endocannabinoid mechanisms of pain modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

SR141716A is an inverse agonist at the human cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

The endocannabinoid system: emotion, learning and addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Anxiolytic-like properties of the anandamide transport inhibitor AM404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Modulation of anxiety through blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Involvement of CB1 cannabinoid receptors in emotional behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

The endogenous cannabinoid system controls extinction of aversive memories

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Depression in association with severe obesity: changes with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Trial comes too late as psychiatric side effects end hope for rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Antiaversive effects of cannabinoids: is the periaqueductal gray involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Effects of cannabidiol (CBD) on regional cerebral blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462009000200012

10.1590/S1516-44462009000200012

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

19578688